官方服务：
资源简介：
Detailed RAL-based regimen backbones.
应用场景：
创建时间：
2019-04-24
相关数据集
Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro
The integrase strand transfer inhibitor (INSTI)-based regimens bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), dolutegravir (DTG)+FTC/TAF, DTG/lamivudine (3TC), and DTG/rilpivirine (RPV
NIAID Data Ecosystem60
Antiretroviral drug exposure in the population studied.
All parameters expressed as median and (interquartile range) unless otherwise specified. ART = Antiretroviral therapy, HAART = Highly active antiretroviral therapy, IP = protease inhibitor, NNRT
NIAID Data Ecosystem30
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial
ObjectivesPrimary study outcome was absence of treatment failure (virological failure, VF, or treatment interruption) per protocol at week 48.MethodsPatients on 3-drug ART with stable HIV-1 RNA Result
Figshare2017-11-22 更新10
Participant characteristics at time of ART initiation.
Participant characteristics at time of ART initiation.
NIAID Data Ecosystem30
Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens
Background and objective: Significant controversy still exists about ritonavir-boosted protease inhibitor monotherapy (mtPI/rtv) as a simplification strategy that is used up to now to treat patients
DataONE2020-06-24 更新30
